The statins in prevention of coronary heart diseases in type 2 diabetics

Bosnian Journal of Basic Medical Sciences

Volumn 9, Issue 1, 2009, Pages 71-76

  Heljic, Becir ^a   Velija Ašimi, Zelija ^a   Kulic, Mehmed ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

Cholesterol; Coronary heart disease; CRP; Diabetes mellitus type 2; Primary; Statin

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; SIMVASTATIN;

EID: 64849083500     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: 10.17305/bjbms.2009.2860     Document Type: Article

References (17)

1. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999; 34o(2):ii5-i26.
2. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 2002; 347:1557-1565.
3. Bellosta S., Ferri N., Arnaboldi L., Bernini F., Paoletti R., Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes-Care. 2000; 23 (Suppl 2): B72-78.
4. Grundy S.M., Cleeman J.I., Bairey Merz C.N., Brewer B. Jr., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
5. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (position statement). Diabetes Care 2006; 29:84-142
6. Riche D.M., McClendon K.S. Role of statins for the primary prevention of cardiovascular disease in patients with Type 2 diabetes mellitus. Am. J. Health-Syst. Pharm. 2007; 64(is):i6o3-i6io.
7. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
8. Knopp R.H., D 'Emden M., Smilde J.G., et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 2006; 29:1478-1485.
9. Wood D. Heart Protection Study, Lancet 2002; 360:7-22.
10. J. Hy-pertens. 1998; 16:1407-1414.
11. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke: systematic review and metaanalysis. B.M.J. 2003; 326: 1423.
12. Sever P.S. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes. Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005; 28:1151-1157.
13. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorva-statin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364:685-696.
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercho-lesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J.A.M.A. 2002; 288:2998-3007.
15. Wanner C. Atorvastatin in patients with type 2 diabetes mellitus undergoing haemodialysis. N. Engl. J. Med. 2005; 353:238-248. (Pubitemid 41058323)
16. Ridker P.M. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003; 108:2292-2297.
17. Gotto A.M. Jr, Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AF-CAPS/TexCAPS). Circulation 2000; 101:477-484.